Category: Behind the Science

Jon Brotchie reports back with highlights from the recent Neuroimmunology Drug Development Summit in Boston, in particular how TREM2 is emerging as one of the most promising new targets for Parkinson’s, both in terms of mechanism and the variety of approaches we have to potentially manipulate it.

The upside of integrating AI into the drug discovery process is potentially game-changing, though it’s also important to be clear-eyed and not get too caught up in the hype. Jon Brotchie reflects on AI’s potential benefits in drug development for Parkinson’s, from finding new and better molecules for novel un-imagined targets, and the repurposing of…

As Parkinson’s becomes the fastest-growing neurological disorder worldwide, its rising prevalence raises urgent questions about public health and economic impact. Could improved diagnosis, treatment, and life expectancy offer a hidden silver lining within the statistics?

At the annual summit of the Society for Neuroscience in Chicago, it was clearer than ever that collaboration and advancing technologies are central to moving the field forward.

Insights from Atuka’s recent visit to the 6th Annual Inflammasome Summit in Boston.

On the encouraging topline results from Cerevel Therapeutics’ Phase III TEMPO-3 trial for tavapadon, a D1/D5 dopamine receptor partial agonist.